Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Amunix to Collaborate With Biogen Idec on Next Generation Long-Lasting Blood Factor Products

By Pharmaceutical Processing | April 13, 2011

Amunix, Inc. today announced that it has entered into an
exclusive worldwide research collaboration and option agreement with Biogen
Idec to research and develop novel, fully-recombinant blood factors (Factors
IX, VIII and VIIa) with improved therapeutic properties. The partnership will
combine Amunix’s protein half-life engineering expertise, based on its
proprietary XTEN technology, and Biogen Idec’s broad range of capabilities in
research, manufacturing and clinical development of recombinant blood factors
for hemophilia.

“Biogen Idec is pleased to initiate research on this
innovative technology in collaboration with Amunix,” said Glenn Pierce,
Senior Vice President of Biogen Idec Hemophilia
(http://www.biogenidechemophilia.com/home.php) . “We have a long-term
commitment to hemophilia. In addition to advancing our current late-stage long-lasting
Factor IX and Factor VIII programs, we continue to invest in innovations like
XTEN, which have the potential to bring further-improved treatment options to
the hemophilia community.”

Under the terms of the agreement, the companies will jointly
conduct preclinical research. Biogen Idec will additionally be responsible for
clinical development, manufacturing and commercialization of therapeutic
candidates selected for further development. Amunix will receive an initial
upfront payment in addition to R&D funding. Amunix will also be eligible to
receive future milestone and royalty payments for therapeutic candidates chosen
by Biogen Idec for development. Additional financial terms will not be
disclosed.

“We are pleased to be collaborating with Biogen Idec, a
global leader in hemophilia therapeutics,” said Willem ‘Pim’ Stemmer,
Ph.D., Chief Executive Officer of Amunix. “Existing recombinant blood
factor products require frequent intravenous infusions and there is strong
medical need for products that can be dosed less frequently and more
conveniently, and used prophylactically. In addition to further validating our
XTEN technology platform, this collaboration with Biogen Idec demonstrates the
potential of the Amunix XTEN technology for recombinant products that require
manufacturing in mammalian cells.”

 

Related Articles Read More >

This is a screenshot from a Varda Space Industries promotional video showing a space capsule with the company's logo docking onto a satellite.
Varda raises $187M Series C for drug manufacturing in space
This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE